While virtually all trials of upfront immune checkpoint inhibition (ICI) for non-small cell lung cancer (NSCLC) stipulate up to two years treatment duration in the study schema, plenty of people question: why stop a good thing? This retrospective look at a nationwide cohort of 1081 patients progression-free at 2 years on ICI for NSCLC reveal only 1 in 5 stop treatment at this time point with no detectable sacrifice in survival with planned two-year discontinuation. | Sun, Jama Oncol 2023
